Home About Contact Add Activities Provider Login

i3 Health

	Applying Precision Medicine in BRAF V600E–Mutant Metastatic Colorectal Cancer STATEMENT OF NEED Colorectal cancer is the second leading cause of cancer death among men and women in the United States (ACS,2021). An estimated 149,500 new cases are diagnosed annually, and 52,980 people die of the disease (ACS, 2021). When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because colorectal cancer initially exhibits no symptoms and ... i3 Health
	Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy CIPN is a complication of cancer treatment that may lead to permanent nerve damage in severe cases. This online activity reviews causative agents, signs and symptoms, and supportive care interventions. 1.0 NCPD \| ILNA STATEMENT OF NEED Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to treatment dose reductio... i3 Health
	Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies Explore best practices in the management of tumor lysis syndrome associated with emerging cancer therapies. This activity, presented by Matthew S. Davids, MD, MMSc, Director of Clinical Research at Dana-Farber Cancer Institute, and Amy Goodrich, RN, BSN, MSN, CRNP-AC, Nurse Practitioner at Johns Hopkins Kimmel Cancer Center, will review plans to optimize prevention, recognition, and treatment, a... i3 Health
	Diagnosis and Evidence-Based Management of T-Cell Lymphoma STATEMENT OF NEED T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis a... i3 Health
	Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma - Part 1 STATEMENT OF NEED Multiple myeloma is a B-cell neoplasm that occurs primarily in older adults. The incidence is expected to rise in conjunction with the aging population. Because symptoms often do not appear until the malignancy is in advanced stages, early diagnosis is difficult, and the 5-year relative survival rate remains only 54% (ACS, 2021). Following diagnosis, management must be guide... i3 Health
	Expert Perspectives on Practice-Changing Strategies for Improved Patient Outcomes in Multiple Myeloma - Part 2 STATEMENT OF NEED Multiple myeloma is a B-cell neoplasm characterized by expansion of plasma cells within the bone marrow and extramedullary sites (ACS, 2021). For patients who relapse, treatment becomes increasingly complex, and outcomes worsen with each relapse (Siegal et al, 2020). Advanced multiple myeloma may be associated with considerable disease-related comorbidities in addition to tr... i3 Health
	Improving Outcomes in Hodgkin Lymphoma This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Start the activity now. STATEMENT OF NEED Hodgkin lymphoma (HL)... i3 Health
	Key Considerations in Managing Atopic Dermatitis in Black Patients Statement of Need Atopic dermatitis (AD), a severe form of eczema and intense pruritus, is associated with a substantial and multifaceted patient-reported burden that encompasses sleep disturbances, anxiety, depression, reduced function/productivity, and impaired quality of life. The incidence of AD is high, estimated to be approximately 15%-20% in children and 1%-3% in adults worldwide (Yong... i3 Health
	Management of Cancer Pain: Current Guidelines STATEMENT OF NEED Patients with cancer often suffer from a range of symptoms that negatively impact their quality of life. Among the most significant of these symptoms is pain, which can be caused by surgery, radiation, chemotherapy, targeted therapy, diagnostic procedures, and/or supportive care measures. Between 20% and 50% of patients with cancer experience pain, including moderate-to-seve... i3 Health
	Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis Learn more about myelofibrosis risk factors, novel therapies to slow disease progression and reduce symptoms, and strategies to maintain quality of life in this comprehensive activity presented by John Mascarenhas, MD, Professor of Medicine at Mount Sinai Icahn School of Medicine. Start the activity now! STATEMENT OF NEED Myelofibrosis is a rare myeloproliferative neoplasm characterized by... i3 Health
	New Data and Emerging Management Strategies for Migraine Headache STATEMENT OF NEED Migraine is a type of chronic headache disorder characterized by headaches of a stabbing, pulsatile quality that last between 4 and 72 hours each, often accompanied by symptoms of nausea and sensitivity to light and noise. An estimated 1.04 billion individuals have been diagnosed with migraine worldwide (Negro et al, 2019). Patients report that migraine impacts virtually eve... i3 Health
	New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia Gain expert insight on new treatment approaches to improve outcomes for patients with immune thrombocytopenia, including individualized treatment for patients who relapse and strategies to alleviate and improve supportive care. This discussion is led by Howard Liebman, MD, Professor of Medicine and Pathology at the University of Southern California Keck School of Medicine, and Allison Miller lma... i3 Health
	New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease STATEMENT OF NEED Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the fi... i3 Health
	New Perspectives in the Management of Marginal Zone Lymphoma STATEMENT OF NEED Marginal zone lymphoma (MZL) comprises approximately 7% of all mature non-Hodgkin lymphomas (NHLs) (Cerhan & Haberman, 2021). According to the World Health Organization classification, there are three subtypes: extranodal MZL, also referred to as mucosa-associated lymphatic tissue (MALT) lymphoma; splenic MZL, which originates from memory B lymphocytes located in the mar... i3 Health
	Nursing Management of Bone Health in Patients with Cancer Once it has metastasized to the skeletal system, cancer often negatively affects bone health, leading to pain, fractures, hypercalcemia, and nerve compression. This online activity reviews interventions to reduce morbodity and mortality of bone complications in patients with cancer. STATEMENT OF NEED Advanced-stage cancers, including lung, breast, prostate, and multiple myeloma, can have ... i3 Health
	Nursing Management of Cancer Treatment-Induced Cardiotoxicity Studies have shown that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. This activity reviews recent advances in the management of cancer teatment-induced cardiotoxicity. STATEMENT OF NEED Several studies reveal that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often ... i3 Health
	Nursing Management of Oral Mucositis Oral mucositis is considered one of the most debilitating side effects of cancer therapy. This online activity reviews pathobiology, risk factors, clinical assessment, and supportive care interventions. STATEMENT OF NEED Oral mucositis (OM) is the inflammation of oral mucosa resulting from cancer therapy and manifesting as atrophy, swelling, erythema, and ulceration (Oronsky et al, 2018). ... i3 Health
	Nursing Management of Venous Thromboembolism in Ambulatory Patients With Cancer VTE is a common and potentially life-threatening complication in patients with cancer. This online activity reviews VTE pathophysiology, risk assessment, and supportive care interventions for ambulatory cancer patients. Venous thromboembolism (VTE) is a common and potentially life-threatening complication in patients with cancer. There are two main types of VTE: deep vein thrombosis (DVT) and... i3 Health
	Nursing Management of Venous Thromboembolism in Hospitalized Patients With Cancer VTE is a life-threatening complication in hospitalized patients with cancer, and is associated with a 2- to 6-fold increase in likelihood of death. This online activity reviews signs and symptoms, risk assessment, and supportive care interventions. STATEMENT OF NEED Venous thromboembolism (VTE), which consists primarily of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a life-t... i3 Health
	Podcast: Applying Precision Medicine in BRAF V600E–Mutant Metastatic Colorectal Cancer STATEMENT OF NEED Colorectal cancer is the second leading cause of cancer death among men and women in the United States (ACS,2021). An estimated 149,500 new cases are diagnosed annually, and 52,980 people die of the disease (ACS, 2021). When detected and treated early at a localized stage, the 5-year survival rate is 90%. However, because colorectal cancer initially exhibits no symptoms and ... i3 Health
	Podcast: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer This expert-led episode of Oncology Data Advisor TM, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine.ain expert insight and enhance your clinical... i3 Health
	Podcast: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer This expert-led episode of Oncology Data Advisor TM, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive ... i3 Health
	Podcast: Key Considerations in Managing Atopic Dermatitis in Black Patients Statement of Need Atopic dermatitis (AD), a severe form of eczema and intense pruritus, is associated with a substantial and multifaceted patient-reported burden that encompasses sleep disturbances, anxiety, depression, reduced function/productivity, and impaired quality of life. The incidence of AD is high, estimated to be approximately 15%-20% in children and 1%-3% in adults worldwide (Yong... i3 Health
	Podcast: New Data and Emerging Management Strategies for Migraine Headache STATEMENT OF NEED Migraine is a type of chronic headache disorder characterized by headaches of a stabbing, pulsatile quality that last between 4 and 72 hours each, often accompanied by symptoms of nausea and sensitivity to light and noise. An estimated 1.04 billion individuals have been diagnosed with migraine worldwide (Negro et al, 2019). Patients report that migraine impacts virtually eve... i3 Health
	Podcast: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing... i3 Health
	Podcast: New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease STATEMENT OF NEED Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the fi... i3 Health
	Podcast: Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This activity is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse ... i3 Health
	Prevention of Medical Errors in Nursing Practice Medical errors are among the most common health-threatening mistakes that affect patient care. This online activity reviews the categories of medication errors, at-risk patient populations, and best practices in error analysis and reporting. STATEMENT OF NEED Medical errors are among the most common health-threatening mistakes that affect patient care, accounting for as many as 250,000 dea... i3 Health
	Therapy of B-Cell Acute Lymphoblastic Leukemia: An Evolving Landscape Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Start the activity now. STATEMENT OF NEED Acute lymphoblastic leukemia (ALL) is a hematologic malignancy char... i3 Health
	Treatment Advances in Waldenstrom Macroglobulinemia In this case-based discussion, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Start the activity now. STATEMENT OF ... i3 Health
	Updates in Mantle Cell Lymphoma Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Start the activity now. ... i3 Health
	Updates in Myelodysplastic Syndromes: Improving Patient Outcomes This activity, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease. Start the activity now. STATEMENT OF NEED Myelodysplastic syn... i3 Health
	Video Viewpoint Strategy Session: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer Gain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of O... i3 Health
	Video Viewpoint Strategy Session: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer This expert-led discussion, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse ev... i3 Health
	Video Viewpoint Strategy Session: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing... i3 Health
	Video Viewpoint Strategy Session: Optimizing Management of Metastatic Squamous Non-Small Cell Lung Cancer Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This activity is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse ... i3 Health
	Video Viewpoint Strategy Session: Optimizing Treatment and Functional Outcomes in Head and Neck Squamous Cell Carcinoma Gain expert insight on emerging treatment approaches for patients with head and neck squamous cell carcinoma, incuding the safety and tolerabilty of emerging treatments, survivorship care, and much more. This activity is presented by leading experts, Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine and Smilow Cancer Hospital, and Lynsey Teulings, NP, Nurse Practitioner at Y... i3 Health

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map